advertisement

Plans to produce

Pfizer Inc.s Covid-19 vaccine in Cape Town may be scaled back because of waning demand for the shots, according to the head of the companys South African manufacturing partner.  

About 100 million doses a year are slated to be packaged and filled at a plant controlled by the

advertisement

BioVac Institute, partly owned by the South African government, which would become the first Southern Hemisphere facility to use the messenger RNA technology underlying the Pfizer-BioNTech version.